A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer
The main purpose of this study is to evaluate the effectiveness of LY2875358 in participants with MET diagnostic positive (+), advanced gastric or gastroesophageal junction (GEJ) cancer.
Gastric Cancer
BIOLOGICAL: LY2875358
Progression Free Survival (PFS) Rate, 8 Weeks
Proportion of Participants who Exhibit Confirmed Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]), Baseline to Confirmed CR or PR (Estimated up to 4 Months)|Proportion of Participants who Exhibit Stable Disease (SD) or Confirmed CR or PR (Disease Control Rate [DCR]), Baseline to Measured Progressive Disease or Death from Any Cause (Estimated up to 4 Months)|Duration of Response, Date of CR or PR to Date of Measured Recurrent or Progressive Disease or Death from Any Cause (Estimated up to 4 Months)|Overall Survival (OS), Baseline to Death from Any Cause (Estimated up to 6 Months)|Pharmacokinetics (PK): Systemic Clearance (CL) of LY287358, Baseline to Study Completion (Estimated up to 4 Months)|Pharmacokinetics (PK): Volume of distribution (V) of LY287358, Baseline to Study Completion (Estimated up to 4 Months)|PFS, Baseline to Measured Progressive Disease or Death from Any Cause (Estimated up to 6 Months)
The main purpose of this study is to evaluate the effectiveness of LY2875358 in participants with MET diagnostic positive (+), advanced gastric or gastroesophageal junction (GEJ) cancer.